Key Highlights

● Omeros fell Friday after the CHMP kept its negative opinion on narsoplimab following re-examination.

● Narsoplimab is sold in the US as YARTEMLEA after FDA clearance in December 2025.

● Omeros will end its EU compassionate-use program and pursue named-patient access instead.

● The Russell 2000 fell 45.90 points to about 2,721 after opening higher.

The regulatory setback

Omeros (NASDAQ:OMER) fell sharply on Friday after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use, known as the CHMP, kept its negative opinion on narsoplimab for the treatment of transplant-associated thrombotic microangiopathy, or TA-TMA. The decision followed a re-examination of the committee's earlier negative opinion, issued in June, according to a company press release and market reports.

TA-TMA is a serious complication that can follow stem-cell transplants. Narsoplimab is already approved in the United States, where it is sold as YARTEMLEA after the Food and Drug Administration cleared it in December 2025, according to the press release.

The company's chief executive did not hide his frustration. "We are deeply disappointed in the re-examination process and outcome," said Gregory A. Demopulos, Chairman and CEO of Omeros.

How far the stock fell

Reports differed on the size of the move. One snapshot showed the shares sinking in mid-morning trading, while another reported a smaller decline, with the stock at $18.30 at the time of its publication. The timing of the two snapshots was not clear. Either way, the Russell 2000 member was among the small-cap health-care names under pressure on a day when the broader market also turned lower.

Alongside the regulatory update, Omeros said it would end its European compassionate-use program for narsoplimab, citing demand for YARTEMLEA in the United States. The company said it would instead pursue named-patient access, a route that allows physicians to request an unapproved medicine for individual patients, according to the press release.

A tough tape for small caps

The broader market offered no cushion. The Russell 2000 fell 45.90 points to about 2,721, according to market data, after opening higher. Another data point put the close at 2,719.57. Over the week, the small-cap index lost about 85.6 points.

Clinical-stage and other long-duration health-care stocks were particularly weak as the 10-year Treasury yield held around 5.1, per market data. Market reports showed sharp declines in names such as Novavax (NASDAQ:NVAX) and PacBio (NASDAQ:PACB), which moved with the sector. Larger health-care companies fared better, with the Health Care Select Sector SPDR Fund reaching a record.

Among large caps, the S&P 500 lost 84.62 points to 7,659.44 and the Nasdaq Composite dropped 572.99 points to 26,140.03, led by a selloff in chip and software stocks. The Dow Jones Industrial Average slipped 175.28 points to 52,002.41.

Omeros Europe Next Steps and YARTEMLEA

For the wider small-cap market, rates remain a key influence. The Federal Reserve's next decision is on Oct 28, and Chair Kevin Warsh said at an IMF gathering in Bangkok, "I don't prejudge meetings." The personal consumption expenditures price index and the first estimate of third-quarter GDP are due Oct 29. Housing starts arrive Oct 20 and the University of Michigan sentiment survey on Oct 23.

For Omeros, attention now turns to the next steps in Europe and to the progress of YARTEMLEA in the U.S. market, which the company highlighted as the reason for winding down its EU compassionate-use program. CHMP opinions are generally passed to the European Commission, which issues the formal decision on marketing authorizations in the European Union. The company has not been reported to have announced further regulatory plans in Europe beyond the named-patient approach.